Business Context and Reporting Period
This Form 8-K Current Report was filed by Mangoceuticals, Inc. (Nasdaq: MGRX) on April 10, 2025. The company is incorporated in Texas and is designated as an emerging growth company. The report primarily addresses Item 5.02 regarding equity compensation awards.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific equity issuance event.
Material Changes
The material change reported is the issuance of 335,000 fully-vested and earned shares of common stock as a discretionary bonus for services rendered during 2025. This issuance was approved by the Board of Directors following a recommendation by the Compensation Committee under the Company's Second Amended and Restated 2022 Equity Plan.
Equity Issuance Breakdown
| Recipient | Position | Shares Issued |
|---|---|---|
| Jacob D. Cohen | Chief Executive Officer and Chairman | 200,000 |
| Antonios Isaac | President and Director | 60,000 |
| Kenny Myers | Director | 25,000 |
| Alex Hamilton | Director | 25,000 |
| Lorraine D'Alessio | Director | 25,000 |
Guidance, Outlook, and Risks
The filing text does not provide forward-looking guidance, management commentary on future operations, specific risk factors, or contingencies beyond the standard disclosure of the equity award.
Investor Verification Checklist
- Verify the total number of shares authorized and remaining under the 2022 Equity Plan following this issuance.
- Confirm the fair market value of the stock on April 10, 2025, to assess the total compensation expense impact.
- Review the Company's most recent 10-Q or 10-K for context on cash burn and liquidity, as this filing does not provide financial statements.
- Check for any subsequent filings regarding the vesting status or trading restrictions on these specific shares.